Aldevron and Integrated DNA Technologies Manufacture
The technically complex, N of 1 therapy required a new guide RNA (gRNA) sequence, new mRNA-encoded base editor, custom off-target safety services and a clinically validated lipid nanoparticle (LNP) formulation, marking an industry milestone.
Share
The technically complex, N of 1 therapy required a new guide RNA (gRNA) sequence, new mRNA-encoded base editor, custom off-target safety services and a clinically validated lipid nanoparticle (LNP) formulation, marking an industry milestone that demonstrates how the U.S. continues to lead the way in mRNA gene editing therapies to improve human health for all. The outcome is featured in a study published today in The New England Journal of Medicine and provides proof of concept for the potential of safe, and effective, personalized CRISPR therapy in the future.
'We are unique in our ability to deliver this innovative treatment in such a short timeline,' said Mark Wetzel, VP/GM mRNA CDMO Services at Aldevron. 'This CRISPR therapy was made under exceptional circumstances—not something our industry is built to do consistently—given the steadfast focus and dedication of the Aldevron and IDT teams to leverage years of expertise and strong partnerships to do what was needed to improve this patient's outcome. Collaboration between Aldevron, IDT, and Acuitas allowed for this innovation to happen, and the future of rare disease treatment is now brighter as a result.'
This accomplishment is complementary to the goal of the Danaher-IGI Beacon for CRISPR Cures to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating diseases. Launched in January 2024, the Beacon unites the finest scientific minds in gene editing at the IGI, with the R&D and manufacturing talent, technology and expertise from across Danaher's various operating companies, to create transformative solutions.
'What we've accomplished together sets a new gold standard for operationalizing the future of medicine,' said Sandy Ottensmann, VP/GM, Gene Writing & Editing at IDT. 'The implications of this work are profound and illuminate how collaborations between academic medicine and industry can enable major science wins. The opportunity ahead lies in continuously leveraging our CRISPR toolbox to innovate and operationalize more potential treatments and help patients in desperate search of cures.'
Aldevron provided the mRNA and worked with Acuitas Therapeutics, a private biotechnology company specializing in the development of LNP delivery systems for nucleic acid therapeutics. Together with the gRNA and safety services provided by IDT, the companies delivered a customized in vivo base-editing therapy, in a significantly compressed timeline, as a transformational therapy for the infant patient. Collaboration between all partners' quality and regulatory teams also led to successful EIND approvals.
'This study is an important milestone,' said corresponding author of the NEJM study Kiran Musunuru, MD, PhD, MPH, ML, MRA, the Barry J. Gertz Professor for Translational Research and Director of the Genetic and Epigenetic Origins of Disease Program in the Perelman School of Medicine at the University of Pennsylvania. 'The impact of this work extends beyond this particular patient and category of clinical indications—it suggests a potential roadmap for transforming CRISPR therapies for other inborn errors of metabolism and life-threatening genetic diseases. It's an exciting future for personalized medicine.'
The patient was treated at CHOP by co-corresponding author and physician-scientist, Rebecca C. Ahrens-Nicklas, MD, PhD. The infant, who was diagnosed with UCD, suffered from neonatal-onset CPS1 deficiency and was unable to remove ammonia from the body.
To learn more about Aldevron and IDT's capabilities, visit www.dhrls.co/aldevronidtworldsfirst.
About Aldevron
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us and follow the company on LinkedIn, Facebook and YouTube.
About IDT
Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.
IDT is proud to be part of Danaher, a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.
For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, Facebook, YouTube, and Instagram.
Disclaimer: CGMP refers to products manufactured under ICHQ7; IDT engineering runs and CGMP gRNA are for development and investigational use only. The performance characteristics of this product have not been established. This product is not intended to be used as final drug product. The purchaser is solely responsible for all decisions regarding the intended use of the product and any associated legal or regulatory obligations.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Fidelis Insurance Holdings' (NYSE:FIHL) Shareholders Will Receive A Bigger Dividend Than Last Year
Fidelis Insurance Holdings Limited (NYSE:FIHL) will increase its dividend on the 26th of September to $0.15, which is 50% higher than last year's payment from the same period of $0.10. This makes the dividend yield 2.4%, which is above the industry average. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Fidelis Insurance Holdings' Projections Indicate Future Payments May Be Unsustainable Estimates Indicate Fidelis Insurance Holdings' Could Struggle to Maintain Dividend Payments In The Future Fidelis Insurance Holdings' Future Dividends May Potentially Be At Risk While it is great to have a strong dividend yield, we should also consider whether the payment is sustainable. Fidelis Insurance Holdings is not generating a profit, but its free cash flows easily cover the dividend, leaving plenty for reinvestment in the business. We generally think that cash flow is more important than accounting measures of profit, so we are fairly comfortable with the dividend at this level. EPS is forecast to rise very quickly over the next 12 months. Assuming the dividend continues along recent trends, we could see the payout ratio reach 222%, which is on the unsustainable side. View our latest analysis for Fidelis Insurance Holdings Fidelis Insurance Holdings Doesn't Have A Long Payment History It's not possible for us to make a backward looking judgement just based on a short payment history. This doesn't mean that the company can't pay a good dividend, but just that we want to wait until it can prove itself. Fidelis Insurance Holdings Could Grow Its Dividend The company's investors will be pleased to have been receiving dividend income for some time. Fidelis Insurance Holdings has impressed us by growing EPS at 8.0% per year over the past five years. Even though the company isn't making a profit, strong earnings growth could turn that around in the near future. As long as the company becomes profitable soon, it is on a trajectory that could see it being a solid dividend payer. In Summary Overall, this is probably not a great income stock, even though the dividend is being raised at the moment. The company is generating plenty of cash, which could maintain the dividend for a while, but the track record hasn't been great. We would probably look elsewhere for an income investment. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. As an example, we've identified 1 warning sign for Fidelis Insurance Holdings that you should be aware of before investing. Is Fidelis Insurance Holdings not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Results: NCR Atleos Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates
Explore NCR Atleos's Fair Values from the Community and select yours NCR Atleos Corporation (NYSE:NATL) investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beating expectations by 2.0% to hit US$1.1b. NCR Atleos also reported a statutory profit of US$0.60, which was an impressive 22% above what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Taking into account the latest results, NCR Atleos' six analysts currently expect revenues in 2025 to be US$4.35b, approximately in line with the last 12 months. Per-share earnings are expected to leap 47% to US$2.56. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$4.31b and earnings per share (EPS) of US$2.55 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates. Check out our latest analysis for NCR Atleos With the analysts reconfirming their revenue and earnings forecasts, it's surprising to see that the price target rose 12% to US$44.67. It looks as though they previously had some doubts over whether the business would live up to their expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on NCR Atleos, with the most bullish analyst valuing it at US$60.00 and the most bearish at US$34.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that NCR Atleos is forecast to grow faster in the future than it has in the past, with revenues expected to display 3.7% annualised growth until the end of 2025. If achieved, this would be a much better result than the 0.5% annual decline over the past year. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 8.0% annually for the foreseeable future. Although NCR Atleos' revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry. The Bottom Line The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for NCR Atleos going out to 2027, and you can see them free on our platform here. Plus, you should also learn about the 2 warning signs we've spotted with NCR Atleos (including 1 which is concerning) . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Consolidated Edison Second Quarter 2025 Earnings: Beats Expectations
Explore Consolidated Edison's Fair Values from the Community and select yours Consolidated Edison (NYSE:ED) Second Quarter 2025 Results Key Financial Results Revenue: US$3.60b (up 12% from 2Q 2024). Net income: US$246.0m (up 22% from 2Q 2024). Profit margin: 6.8% (up from 6.3% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: US$0.68 (up from US$0.58 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Consolidated Edison Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) also surpassed analyst estimates by 1.2%. Looking ahead, revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Integrated Utilities industry in the US. Performance of the American Integrated Utilities industry. The company's share price is broadly unchanged from a week ago. Risk Analysis Before we wrap up, we've discovered 2 warning signs for Consolidated Edison (1 is concerning!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
